APP and Alzheimer disease: Western blot analysis of brain tissues from the AD-Veh and AD-ALA groups showed that ALA treatment in vivo decreased the levels of APP and of the β-secretase cleavage products C99 and C89, but not the expression of β- and γ-secretases (Fig. 2E, G, K-N).